Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2020. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them, specifically Ms. D. Waterhouse, CEO of ViiV Healthcare.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for GSK Plc. It details a specific executive compensation event:
- Transaction Type: Cash payment following the vesting of a Deferred Investment Award.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Volume: 14,421.337 notional Ordinary Shares.
- Price: £16.686 per share.
- Payment Amount: £240,634.43 (gross, less applicable tax withholding).
- Date of Transaction: February 16, 2020.
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely discloses the vesting of 25% of an award originally made on February 16, 2015.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of a specific equity-based compensation event.
Key Facts for Investor Verification
- Verify the vesting schedule and terms of the GlaxoSmithKline Deferred Investment Award programme.
- Confirm the tax withholding implications for the £240,634.43 gross payment to Ms. Waterhouse.
- Note that this transaction involves notional shares resulting in a cash payout, not a direct issuance of new shares to the market.